3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Pancreatic Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
34
Cisplatin
12
Nivolumab
10
atezolizumab
9
Docetaxel
9
Carboplatin
9
Paclitaxel
8
Cetuximab
8
Gemcitabine
7
Blood Specimen Collection
7
Radiotherapy
6
Fluorouracil
6
Drug Therapy
6
cemiplimab
5
Pemetrexed
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Standard of Care
4
Cyclophosphamide
4
spartalizumab
3
epacadostat
3
Surveys and Questionnaires
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Interleukin-2
3
Filgrastim
3
Bupropion
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
tisotumab vedotin
×
Thoracic
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled